We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTNT
126
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.71M 0.07%
22,927
+7,948
+53% +$2.06M
INGN icon
127
Inogen
INGN
$167M
$4.32M 0.06%
148,912
– –
GOCO
128
DELISTED
GoHealth
GOCO
$4.1M 0.06%
+20,978
New +$5.05M
OM icon
129
Outset Medical
OM
$74.9M
$4M 0.06%
+5,328
New +$4.38M
NUVA
130
DELISTED
NuVasive, Inc.
NUVA
$3.99M 0.06%
82,100
+15,600
+23% +$841K
BNR
131
Burning Rock Biotech
BNR
$3.68M 0.05%
14,676
+10,176
+226% +$2.41M
BNTX icon
132
BioNTech
BNTX
$22.6B
$3.43M 0.05%
49,500
-500
-1% -$35.9K
RARE icon
133
Ultragenyx Pharmaceutical
RARE
$2.65B
$3.37M 0.05%
41,000
+17,000
+71% +$1.41M
ABBV icon
134
AbbVie
ABBV
$458B
$3.24M 0.04%
37,000
– –
NBP
135
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$3.06M 0.04%
+65,000
New +$2.14M
MRTX
136
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.96M 0.04%
17,800
– –
SNY icon
137
Sanofi
SNY
$104B
$2.86M 0.04%
57,000
– –
SRPT icon
138
Sarepta Therapeutics
SRPT
$1.66B
$2.85M 0.04%
20,300
– –
PFE icon
139
Pfizer
PFE
$140B
$2.71M 0.04%
+77,891
New +$2.73M
BIIB icon
140
Biogen
BIIB
$29.9B
$2.44M 0.03%
+8,600
New +$2.4M
ASND icon
141
Ascendis Pharma A/S
ASND
$16.7B
$2.39M 0.03%
15,500
+2,200
+17% +$316K
CVAC
142
DELISTED
CureVac
CVAC
$2.35M 0.03%
+50,500
New +$2.82M
KYNB
143
Kyntra Bio
KYNB
$28.5M
$2.18M 0.03%
+2,120
New +$2.28M
GTH
144
DELISTED
Genetron Holdings Limited ADS
GTH
$1.92M 0.03%
53,470
+20,137
+60% +$775K
ACAD icon
145
Acadia Pharmaceuticals
ACAD
$4.25B
$1.85M 0.03%
44,900
– –
BMY.RT
146
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$1.8M 0.02%
800,000
– –
BHVN
147
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.59M 0.02%
+24,500
New +$1.61M
CLLS
148
Cellectis
CLLS
$286M
$1.54M 0.02%
83,500
– –
KURA icon
149
Kura Oncology
KURA
$922M
$1.47M 0.02%
+48,000
New +$1.06M
QURE icon
150
uniQure
QURE
$2.68B
$1.27M 0.02%
34,500
– –
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.